APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chemotherapy Induced Neutropenia Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Chemotherapy Induced Neutropenia Drug Industry Growth and Trends Forecast to 2032

19 December 2025128 pages

Choose your research edition.

Industry ResearchChemotherapy Induced Neutropenia Drug Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Chemotherapy Induced Neutropenia Drug Industry Growth and Trends Forecast to 2032128 pages · $3,450 USDMarket StructureGlobal Chemotherapy Induced Neutropenia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chemotherapy Induced Neutropenia Drug Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Chemotherapy Induced Neutropenia Drug Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Chemotherapy Induced Neutropenia Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Chemotherapy Induced Neutropenia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Chemotherapy Induced Neutropenia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chemotherapy Induced Neutropenia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Chemotherapy Induced Neutropenia Drug include Sandoz International GmbH, Pfizer Inc, USV Pvt Ltd, Richter Gedeon Nyrt, Reliance Life Sciences Pvt Ltd, Pfenex Inc, Pangen Biotech Inc., Octapharma AG and Nohla Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Chemotherapy Induced Neutropenia Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Chemotherapy Induced Neutropenia Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Chemotherapy Induced Neutropenia Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Chemotherapy Induced Neutropenia Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Chemotherapy Induced Neutropenia Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Chemotherapy Induced Neutropenia Drug Market by Company

Sandoz International GmbH

Pfizer Inc

USV Pvt Ltd

Richter Gedeon Nyrt

Reliance Life Sciences Pvt Ltd

Pfenex Inc

Pangen Biotech Inc.

Octapharma AG

Nohla Therapeutics Inc

Myelo Therapeutics GmbH

Mycenax Biotech Inc

Lupin Ltd

Intas Pharmaceuticals Ltd

Hanmi Pharmaceuticals Co Ltd

GlycoMimetics Inc

Genexine Inc

Generon (Shanghai) Corp Ltd

Gene Techno Science Co Ltd

Dr. Reddy's Laboratories Ltd

Cinfa Biotech SL

Chong Kun Dang Pharmaceutical Corp

Cellerant Therapeutics Inc

Bolder Biotechnology Inc

Biocon Ltd

BeyondSpring Pharmaceuticals Inc

Chemotherapy Induced Neutropenia Drug Segment by Type

Filgrastim

NLA-101

GW-003

F-627

BBT-018

Others

Chemotherapy Induced Neutropenia Drug Segment by Application

Hospital

Clinic

Others

Chemotherapy Induced Neutropenia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotherapy Induced Neutropenia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chemotherapy Induced Neutropenia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotherapy Induced Neutropenia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Chemotherapy Induced Neutropenia Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Chemotherapy Induced Neutropenia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Filgrastim Table 2. Major Company of NLA-101 Table 3. Major Company of GW-003 Table 4. Major Company of F-627 Table 5. Major Company of BBT-018 Table 6. Major Company of Others Table 7. Global Chemotherapy Induced Neutropenia Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2026) & (K Units) Table 9. Global Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Type (2021-2026) Table 10. Global Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2026) & (US$ Million) Table 11. Global Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Type (2021-2026) Table 12. Global Chemotherapy Induced Neutropenia Drug Price by Type (2021-2026) & (US$/Unit) Table 13. Global Chemotherapy Induced Neutropenia Drug Sales by Type (2027-2032) & (K Units) Table 14. Global Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Type (2027-2032) Table 15. Global Chemotherapy Induced Neutropenia Drug Sales by Type (2027-2032) & (US$ Million) Table 16. Global Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Type (2027-2032) Table 17. Global Chemotherapy Induced Neutropenia Drug Price by Type (2027-2032) & (US$/Unit) Table 18. North America Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2026) & (K Units) Table 19. North America Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2026) & (K Units) Table 21. Europe Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2026) & (K Units) Table 23. Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2026) & (K Units) Table 25. Latin America Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2026) & (K Units) Table 27. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2026) & (US$ Million) Table 28. Chemotherapy Induced Neutropenia Drug Industry Trends Table 29. Chemotherapy Induced Neutropenia Drug Industry Drivers Table 30. Chemotherapy Induced Neutropenia Drug Industry Opportunities and Challenges Table 31. Chemotherapy Induced Neutropenia Drug Industry Restraints Table 32. Global Chemotherapy Induced Neutropenia Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Company (2021-2026) Table 34. Global Chemotherapy Induced Neutropenia Drug Sales by Company (2021-2026) & (K Units) Table 35. Global Chemotherapy Induced Neutropenia Drug Sales Share by Company (2021-2026) Table 36. Global Chemotherapy Induced Neutropenia Drug Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Chemotherapy Induced Neutropenia Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Chemotherapy Induced Neutropenia Drug Major Company Production Sites and Headquarters Table 39. Global Chemotherapy Induced Neutropenia Drug Company, Product Type & Application Table 40. Global Chemotherapy Induced Neutropenia Drug Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Chemotherapy Induced Neutropenia Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Chemotherapy Induced Neutropenia Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Chemotherapy Induced Neutropenia Drug Sales by Region (2021-2026) & (K Units) Table 45. Global Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Region (2021-2026) Table 46. Global Chemotherapy Induced Neutropenia Drug Sales by Region (2021-2026) & (US$ Million) Table 47. Global Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Region (2021-2026) Table 48. Global Chemotherapy Induced Neutropenia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Chemotherapy Induced Neutropenia Drug Sales by Region (2027-2032) & (K Units) Table 50. Global Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Region (2027-2032) Table 51. Global Chemotherapy Induced Neutropenia Drug Sales by Region (2027-2032) & (US$ Million) Table 52. Global Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Region (2027-2032) Table 53. Global Chemotherapy Induced Neutropenia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Chemotherapy Induced Neutropenia Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2026) & (K Units) Table 56. Global Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Application (2021-2026) Table 57. Global Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2026) & (US$ Million) Table 58. Global Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Application (2021-2026) Table 59. Global Chemotherapy Induced Neutropenia Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Chemotherapy Induced Neutropenia Drug Sales by Application (2027-2032) & (K Units) Table 61. Global Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Application (2027-2032) Table 62. Global Chemotherapy Induced Neutropenia Drug Sales by Application (2027-2032) & (US$ Million) Table 63. Global Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Application (2027-2032) Table 64. Global Chemotherapy Induced Neutropenia Drug Price by Application (2027-2032) & (US$/Unit) Table 65. North America Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2026) & (K Units) Table 66. North America Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2026) & (K Units) Table 68. Europe Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2026) & (K Units) Table 70. Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2026) & (K Units) Table 72. Latin America Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2026) & (K Units) Table 74. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2026) & (US$ Million) Table 75. Sandoz International GmbH Company Information Table 76. Sandoz International GmbH Business Overview Table 77. Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Product Portfolio Table 79. Sandoz International GmbH Recent Development Table 80. Pfizer Inc Company Information Table 81. Pfizer Inc Business Overview Table 82. Pfizer Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Pfizer Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 84. Pfizer Inc Recent Development Table 85. USV Pvt Ltd Company Information Table 86. USV Pvt Ltd Business Overview Table 87. USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 89. USV Pvt Ltd Recent Development Table 90. Richter Gedeon Nyrt Company Information Table 91. Richter Gedeon Nyrt Business Overview Table 92. Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Product Portfolio Table 94. Richter Gedeon Nyrt Recent Development Table 95. Reliance Life Sciences Pvt Ltd Company Information Table 96. Reliance Life Sciences Pvt Ltd Business Overview Table 97. Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 99. Reliance Life Sciences Pvt Ltd Recent Development Table 100. Pfenex Inc Company Information Table 101. Pfenex Inc Business Overview Table 102. Pfenex Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Pfenex Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 104. Pfenex Inc Recent Development Table 105. Pangen Biotech Inc. Company Information Table 106. Pangen Biotech Inc. Business Overview Table 107. Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Product Portfolio Table 109. Pangen Biotech Inc. Recent Development Table 110. Octapharma AG Company Information Table 111. Octapharma AG Business Overview Table 112. Octapharma AG Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Octapharma AG Chemotherapy Induced Neutropenia Drug Product Portfolio Table 114. Octapharma AG Recent Development Table 115. Nohla Therapeutics Inc Company Information Table 116. Nohla Therapeutics Inc Business Overview Table 117. Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 119. Nohla Therapeutics Inc Recent Development Table 120. Myelo Therapeutics GmbH Company Information Table 121. Myelo Therapeutics GmbH Business Overview Table 122. Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Product Portfolio Table 124. Myelo Therapeutics GmbH Recent Development Table 125. Mycenax Biotech Inc Company Information Table 126. Mycenax Biotech Inc Business Overview Table 127. Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 129. Mycenax Biotech Inc Recent Development Table 130. Lupin Ltd Company Information Table 131. Lupin Ltd Business Overview Table 132. Lupin Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Lupin Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 134. Lupin Ltd Recent Development Table 135. Intas Pharmaceuticals Ltd Company Information Table 136. Intas Pharmaceuticals Ltd Business Overview Table 137. Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 139. Intas Pharmaceuticals Ltd Recent Development Table 140. Hanmi Pharmaceuticals Co Ltd Company Information Table 141. Hanmi Pharmaceuticals Co Ltd Business Overview Table 142. Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 144. Hanmi Pharmaceuticals Co Ltd Recent Development Table 145. GlycoMimetics Inc Company Information Table 146. GlycoMimetics Inc Business Overview Table 147. GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 149. GlycoMimetics Inc Recent Development Table 150. Genexine Inc Company Information Table 151. Genexine Inc Business Overview Table 152. Genexine Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Genexine Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 154. Genexine Inc Recent Development Table 155. Generon (Shanghai) Corp Ltd Company Information Table 156. Generon (Shanghai) Corp Ltd Business Overview Table 157. Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 159. Generon (Shanghai) Corp Ltd Recent Development Table 160. Gene Techno Science Co Ltd Company Information Table 161. Gene Techno Science Co Ltd Business Overview Table 162. Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 163. Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 164. Gene Techno Science Co Ltd Recent Development Table 165. Dr. Reddy's Laboratories Ltd Company Information Table 166. Dr. Reddy's Laboratories Ltd Business Overview Table 167. Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 168. Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 169. Dr. Reddy's Laboratories Ltd Recent Development Table 170. Cinfa Biotech SL Company Information Table 171. Cinfa Biotech SL Business Overview Table 172. Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 173. Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Product Portfolio Table 174. Cinfa Biotech SL Recent Development Table 175. Chong Kun Dang Pharmaceutical Corp Company Information Table 176. Chong Kun Dang Pharmaceutical Corp Business Overview Table 177. Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 178. Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Product Portfolio Table 179. Chong Kun Dang Pharmaceutical Corp Recent Development Table 180. Cellerant Therapeutics Inc Company Information Table 181. Cellerant Therapeutics Inc Business Overview Table 182. Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 183. Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 184. Cellerant Therapeutics Inc Recent Development Table 185. Bolder Biotechnology Inc Company Information Table 186. Bolder Biotechnology Inc Business Overview Table 187. Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 188. Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 189. Bolder Biotechnology Inc Recent Development Table 190. Biocon Ltd Company Information Table 191. Biocon Ltd Business Overview Table 192. Biocon Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 193. Biocon Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 194. Biocon Ltd Recent Development Table 195. BeyondSpring Pharmaceuticals Inc Company Information Table 196. BeyondSpring Pharmaceuticals Inc Business Overview Table 197. BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 198. BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 199. BeyondSpring Pharmaceuticals Inc Recent Development Table 200. North America Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 201. North America Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026) & (K Units) Table 202. North America Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2021-2026) Table 203. North America Chemotherapy Induced Neutropenia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 204. North America Chemotherapy Induced Neutropenia Drug Sales Market Share Forecast by Country (2027-2032) Table 205. North America Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 206. North America Chemotherapy Induced Neutropenia Drug Market Size by Country (2021-2026) & (US$ Million) Table 207. North America Chemotherapy Induced Neutropenia Drug Market Share by Country (2021-2026) Table 208. North America Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 209. North America Chemotherapy Induced Neutropenia Drug Market Share Forecast by Country (2027-2032) Table 210. Europe Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 211. Europe Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026) & (K Units) Table 212. Europe Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2021-2026) Table 213. Europe Chemotherapy Induced Neutropenia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 214. Europe Chemotherapy Induced Neutropenia Drug Sales Market Share Forecast by Country (2027-2032) Table 215. Europe Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 216. Europe Chemotherapy Induced Neutropenia Drug Market Size by Country (2021-2026) & (US$ Million) Table 217. Europe Chemotherapy Induced Neutropenia Drug Market Share by Country (2021-2026) Table 218. Europe Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 219. Europe Chemotherapy Induced Neutropenia Drug Market Share Forecast by Country (2027-2032) Table 220. Asia-Pacific Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 221. Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026) & (K Units) Table 222. Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2021-2026) Table 223. Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 224. Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales Market Share Forecast by Country (2027-2032) Table 225. Asia-Pacific Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 226. Asia-Pacific Chemotherapy Induced Neutropenia Drug Market Size by Country (2021-2026) & (US$ Million) Table 227. Asia-Pacific Chemotherapy Induced Neutropenia Drug Market Share by Country (2021-2026) Table 228. Asia-Pacific Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 229. Asia-Pacific Chemotherapy Induced Neutropenia Drug Market Share Forecast by Country (2027-2032) Table 230. Latin America Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 231. Latin America Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026) & (K Units) Table 232. Latin America Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2021-2026) Table 233. Latin America Chemotherapy Induced Neutropenia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 234. Latin America Chemotherapy Induced Neutropenia Drug Sales Market Share Forecast by Country (2027-2032) Table 235. Latin America Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 236. Latin America Chemotherapy Induced Neutropenia Drug Market Size by Country (2021-2026) & (US$ Million) Table 237. Latin America Chemotherapy Induced Neutropenia Drug Market Share by Country (2021-2026) Table 238. Latin America Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 239. Latin America Chemotherapy Induced Neutropenia Drug Market Share Forecast by Country (2027-2032) Table 240. Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 241. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026) & (K Units) Table 242. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2021-2026) Table 243. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Forecast by Country (2027-2032) & (K Units) Table 244. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Market Share Forecast by Country (2027-2032) Table 245. Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 246. Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Size by Country (2021-2026) & (US$ Million) Table 247. Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Share by Country (2021-2026) Table 248. Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 249. Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Share Forecast by Country (2027-2032) Table 250. Key Raw Materials Table 251. Raw Materials Key Suppliers Table 252. Chemotherapy Induced Neutropenia Drug Distributors List Table 253. Chemotherapy Induced Neutropenia Drug Customers List Table 254. Research Programs/Design for This Report Table 255. Authors List of This Report Table 256. Secondary Sources Table 257. Primary Sources List of Figures Figure 1. Chemotherapy Induced Neutropenia Drug Image Figure 2. Global Chemotherapy Induced Neutropenia Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chemotherapy Induced Neutropenia Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Chemotherapy Induced Neutropenia Drug Sales (2021-2032) & (K Units) Figure 5. Filgrastim Image Figure 6. Global Filgrastim Sales YoY Growth (2021-2032) & (K Units) Figure 7. NLA-101 Image Figure 8. Global NLA-101 Sales YoY Growth (2021-2032) & (K Units) Figure 9. GW-003 Image Figure 10. Global GW-003 Sales YoY Growth (2021-2032) & (K Units) Figure 11. F-627 Image Figure 12. Global F-627 Sales YoY Growth (2021-2032) & (K Units) Figure 13. BBT-018 Image Figure 14. Global BBT-018 Sales YoY Growth (2021-2032) & (K Units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 17. Global Chemotherapy Induced Neutropenia Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Chemotherapy Induced Neutropenia Drug Market Share by Type 2025 VS 2032 Figure 19. North America Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Type in 2025 Figure 20. North America Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Type in 2025 Figure 21. Europe Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Type in 2025 Figure 22. Europe Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Type in 2025 Figure 25. Latin America Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Chemotherapy Induced Neutropenia Drug Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Hospital Image Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 33. Clinic Image Figure 34. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 35. Others Image Figure 36. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 37. Global Chemotherapy Induced Neutropenia Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Chemotherapy Induced Neutropenia Drug Market Share by Application 2025 VS 2032 Figure 39. North America Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Application in 2025 Figure 40. North America Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Application in 2025 Figure 41. Europe Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Application in 2025 Figure 42. Europe Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Application in 2025 Figure 45. Latin America Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Market Share in Value by Application in 2025 Figure 49. North America Chemotherapy Induced Neutropenia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. North America Chemotherapy Induced Neutropenia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Chemotherapy Induced Neutropenia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Chemotherapy Induced Neutropenia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Chemotherapy Induced Neutropenia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Europe Chemotherapy Induced Neutropenia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Chemotherapy Induced Neutropenia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Chemotherapy Induced Neutropenia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Chemotherapy Induced Neutropenia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Chemotherapy Induced Neutropenia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Chemotherapy Induced Neutropenia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Latin America Chemotherapy Induced Neutropenia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Chemotherapy Induced Neutropenia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Chemotherapy Induced Neutropenia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 66. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Chemotherapy Induced Neutropenia Drug Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Chemotherapy Induced Neutropenia Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Filgrastim
  • NLA-101
  • GW-003
  • F-627
  • BBT-018
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Sandoz International GmbH
  • Pfizer Inc
  • USV Pvt Ltd
  • Richter Gedeon Nyrt
  • Reliance Life Sciences Pvt Ltd
  • Pfenex Inc
  • Pangen Biotech Inc.
  • Octapharma AG
  • Nohla Therapeutics Inc
  • Myelo Therapeutics GmbH
  • Mycenax Biotech Inc
  • Lupin Ltd
  • Intas Pharmaceuticals Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • GlycoMimetics Inc
  • Genexine Inc
  • Generon (Shanghai) Corp Ltd
  • Gene Techno Science Co Ltd
  • Dr. Reddy's Laboratories Ltd
  • Cinfa Biotech SL
  • Chong Kun Dang Pharmaceutical Corp
  • Cellerant Therapeutics Inc
  • Bolder Biotechnology Inc
  • Biocon Ltd
  • BeyondSpring Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Chemotherapy Induced Neutropenia Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Chemotherapy Induced Neutropenia Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Chemotherapy Induced Neutropenia Drug Market by Type
  6. 1.3.1 Filgrastim
  7. 1.3.2 NLA-101
  8. 1.3.3 GW-003
  9. 1.3.4 F-627
  10. 1.3.5 BBT-018
  11. 1.3.6 Others
  12. 1.4 Global Chemotherapy Induced Neutropenia Drug Market Size by Type
  13. 1.4.1 Global Chemotherapy Induced Neutropenia Drug Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Chemotherapy Induced Neutropenia Drug Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Chemotherapy Induced Neutropenia Drug Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Chemotherapy Induced Neutropenia Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Chemotherapy Induced Neutropenia Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Chemotherapy Induced Neutropenia Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Chemotherapy Induced Neutropenia Drug Industry Trends
  2. 2.2 Chemotherapy Induced Neutropenia Drug Industry Drivers
  3. 2.3 Chemotherapy Induced Neutropenia Drug Industry Opportunities and Challenges
  4. 2.4 Chemotherapy Induced Neutropenia Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Chemotherapy Induced Neutropenia Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Chemotherapy Induced Neutropenia Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Chemotherapy Induced Neutropenia Drug Price (2021-2026)
  4. 3.4 Global Chemotherapy Induced Neutropenia Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Chemotherapy Induced Neutropenia Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Chemotherapy Induced Neutropenia Drug Company, Product Type & Application
  7. 3.7 Global Chemotherapy Induced Neutropenia Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Chemotherapy Induced Neutropenia Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Chemotherapy Induced Neutropenia Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Chemotherapy Induced Neutropenia Drug Tier 1, Tier 2, and Tier 3
4 Chemotherapy Induced Neutropenia Drug Regional Status and Outlook
  1. 4.1 Global Chemotherapy Induced Neutropenia Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Chemotherapy Induced Neutropenia Drug Historic Market Size by Region
  3. 4.2.1 Global Chemotherapy Induced Neutropenia Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Chemotherapy Induced Neutropenia Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Chemotherapy Induced Neutropenia Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Chemotherapy Induced Neutropenia Drug Forecasted Market Size by Region
  7. 4.3.1 Global Chemotherapy Induced Neutropenia Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Chemotherapy Induced Neutropenia Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Chemotherapy Induced Neutropenia Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Chemotherapy Induced Neutropenia Drug by Application
  1. 5.1 Chemotherapy Induced Neutropenia Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Chemotherapy Induced Neutropenia Drug Market Size by Application
  6. 5.2.1 Global Chemotherapy Induced Neutropenia Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Chemotherapy Induced Neutropenia Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Chemotherapy Induced Neutropenia Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Chemotherapy Induced Neutropenia Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Chemotherapy Induced Neutropenia Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Chemotherapy Induced Neutropenia Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sandoz International GmbH
  2. 6.1.1 Sandoz International GmbH Company Information
  3. 6.1.2 Sandoz International GmbH Business Overview
  4. 6.1.3 Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Product Portfolio
  6. 6.1.5 Sandoz International GmbH Recent Developments
  7. 6.2 Pfizer Inc
  8. 6.2.1 Pfizer Inc Company Information
  9. 6.2.2 Pfizer Inc Business Overview
  10. 6.2.3 Pfizer Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Pfizer Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  12. 6.2.5 Pfizer Inc Recent Developments
  13. 6.3 USV Pvt Ltd
  14. 6.3.1 USV Pvt Ltd Company Information
  15. 6.3.2 USV Pvt Ltd Business Overview
  16. 6.3.3 USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  18. 6.3.5 USV Pvt Ltd Recent Developments
  19. 6.4 Richter Gedeon Nyrt
  20. 6.4.1 Richter Gedeon Nyrt Company Information
  21. 6.4.2 Richter Gedeon Nyrt Business Overview
  22. 6.4.3 Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Product Portfolio
  24. 6.4.5 Richter Gedeon Nyrt Recent Developments
  25. 6.5 Reliance Life Sciences Pvt Ltd
  26. 6.5.1 Reliance Life Sciences Pvt Ltd Company Information
  27. 6.5.2 Reliance Life Sciences Pvt Ltd Business Overview
  28. 6.5.3 Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  30. 6.5.5 Reliance Life Sciences Pvt Ltd Recent Developments
  31. 6.6 Pfenex Inc
  32. 6.6.1 Pfenex Inc Company Information
  33. 6.6.2 Pfenex Inc Business Overview
  34. 6.6.3 Pfenex Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfenex Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  36. 6.6.5 Pfenex Inc Recent Developments
  37. 6.7 Pangen Biotech Inc.
  38. 6.7.1 Pangen Biotech Inc. Company Information
  39. 6.7.2 Pangen Biotech Inc. Business Overview
  40. 6.7.3 Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Product Portfolio
  42. 6.7.5 Pangen Biotech Inc. Recent Developments
  43. 6.8 Octapharma AG
  44. 6.8.1 Octapharma AG Company Information
  45. 6.8.2 Octapharma AG Business Overview
  46. 6.8.3 Octapharma AG Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Octapharma AG Chemotherapy Induced Neutropenia Drug Product Portfolio
  48. 6.8.5 Octapharma AG Recent Developments
  49. 6.9 Nohla Therapeutics Inc
  50. 6.9.1 Nohla Therapeutics Inc Company Information
  51. 6.9.2 Nohla Therapeutics Inc Business Overview
  52. 6.9.3 Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  54. 6.9.5 Nohla Therapeutics Inc Recent Developments
  55. 6.10 Myelo Therapeutics GmbH
  56. 6.10.1 Myelo Therapeutics GmbH Company Information
  57. 6.10.2 Myelo Therapeutics GmbH Business Overview
  58. 6.10.3 Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Product Portfolio
  60. 6.10.5 Myelo Therapeutics GmbH Recent Developments
  61. 6.11 Mycenax Biotech Inc
  62. 6.11.1 Mycenax Biotech Inc Company Information
  63. 6.11.2 Mycenax Biotech Inc Business Overview
  64. 6.11.3 Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  66. 6.11.5 Mycenax Biotech Inc Recent Developments
  67. 6.12 Lupin Ltd
  68. 6.12.1 Lupin Ltd Company Information
  69. 6.12.2 Lupin Ltd Business Overview
  70. 6.12.3 Lupin Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Lupin Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  72. 6.12.5 Lupin Ltd Recent Developments
  73. 6.13 Intas Pharmaceuticals Ltd
  74. 6.13.1 Intas Pharmaceuticals Ltd Company Information
  75. 6.13.2 Intas Pharmaceuticals Ltd Business Overview
  76. 6.13.3 Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  78. 6.13.5 Intas Pharmaceuticals Ltd Recent Developments
  79. 6.14 Hanmi Pharmaceuticals Co Ltd
  80. 6.14.1 Hanmi Pharmaceuticals Co Ltd Company Information
  81. 6.14.2 Hanmi Pharmaceuticals Co Ltd Business Overview
  82. 6.14.3 Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  84. 6.14.5 Hanmi Pharmaceuticals Co Ltd Recent Developments
  85. 6.15 GlycoMimetics Inc
  86. 6.15.1 GlycoMimetics Inc Company Information
  87. 6.15.2 GlycoMimetics Inc Business Overview
  88. 6.15.3 GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  90. 6.15.5 GlycoMimetics Inc Recent Developments
  91. 6.16 Genexine Inc
  92. 6.16.1 Genexine Inc Company Information
  93. 6.16.2 Genexine Inc Business Overview
  94. 6.16.3 Genexine Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Genexine Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  96. 6.16.5 Genexine Inc Recent Developments
  97. 6.17 Generon (Shanghai) Corp Ltd
  98. 6.17.1 Generon (Shanghai) Corp Ltd Company Information
  99. 6.17.2 Generon (Shanghai) Corp Ltd Business Overview
  100. 6.17.3 Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  102. 6.17.5 Generon (Shanghai) Corp Ltd Recent Developments
  103. 6.18 Gene Techno Science Co Ltd
  104. 6.18.1 Gene Techno Science Co Ltd Company Information
  105. 6.18.2 Gene Techno Science Co Ltd Business Overview
  106. 6.18.3 Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  108. 6.18.5 Gene Techno Science Co Ltd Recent Developments
  109. 6.19 Dr. Reddy's Laboratories Ltd
  110. 6.19.1 Dr. Reddy's Laboratories Ltd Company Information
  111. 6.19.2 Dr. Reddy's Laboratories Ltd Business Overview
  112. 6.19.3 Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  114. 6.19.5 Dr. Reddy's Laboratories Ltd Recent Developments
  115. 6.20 Cinfa Biotech SL
  116. 6.20.1 Cinfa Biotech SL Company Information
  117. 6.20.2 Cinfa Biotech SL Business Overview
  118. 6.20.3 Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Product Portfolio
  120. 6.20.5 Cinfa Biotech SL Recent Developments
  121. 6.21 Chong Kun Dang Pharmaceutical Corp
  122. 6.21.1 Chong Kun Dang Pharmaceutical Corp Company Information
  123. 6.21.2 Chong Kun Dang Pharmaceutical Corp Business Overview
  124. 6.21.3 Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Product Portfolio
  126. 6.21.5 Chong Kun Dang Pharmaceutical Corp Recent Developments
  127. 6.22 Cellerant Therapeutics Inc
  128. 6.22.1 Cellerant Therapeutics Inc Company Information
  129. 6.22.2 Cellerant Therapeutics Inc Business Overview
  130. 6.22.3 Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  132. 6.22.5 Cellerant Therapeutics Inc Recent Developments
  133. 6.23 Bolder Biotechnology Inc
  134. 6.23.1 Bolder Biotechnology Inc Company Information
  135. 6.23.2 Bolder Biotechnology Inc Business Overview
  136. 6.23.3 Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  138. 6.23.5 Bolder Biotechnology Inc Recent Developments
  139. 6.24 Biocon Ltd
  140. 6.24.1 Biocon Ltd Company Information
  141. 6.24.2 Biocon Ltd Business Overview
  142. 6.24.3 Biocon Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Biocon Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  144. 6.24.5 Biocon Ltd Recent Developments
  145. 6.25 BeyondSpring Pharmaceuticals Inc
  146. 6.25.1 BeyondSpring Pharmaceuticals Inc Company Information
  147. 6.25.2 BeyondSpring Pharmaceuticals Inc Business Overview
  148. 6.25.3 BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  150. 6.25.5 BeyondSpring Pharmaceuticals Inc Recent Developments
7 North America by Country
  1. 7.1 North America Chemotherapy Induced Neutropenia Drug Sales by Country
  2. 7.1.1 North America Chemotherapy Induced Neutropenia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Chemotherapy Induced Neutropenia Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Chemotherapy Induced Neutropenia Drug Market Size by Country
  6. 7.2.1 North America Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Chemotherapy Induced Neutropenia Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Chemotherapy Induced Neutropenia Drug Sales by Country
  2. 8.1.1 Europe Chemotherapy Induced Neutropenia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Chemotherapy Induced Neutropenia Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Chemotherapy Induced Neutropenia Drug Market Size by Country
  6. 8.2.1 Europe Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Chemotherapy Induced Neutropenia Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales by Country
  2. 9.1.1 Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Chemotherapy Induced Neutropenia Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Chemotherapy Induced Neutropenia Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Chemotherapy Induced Neutropenia Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Chemotherapy Induced Neutropenia Drug Sales by Country
  2. 10.1.1 South America Chemotherapy Induced Neutropenia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Chemotherapy Induced Neutropenia Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Chemotherapy Induced Neutropenia Drug Market Size by Country
  6. 10.2.1 South America Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Chemotherapy Induced Neutropenia Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Country
  2. 11.1.1 Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Chemotherapy Induced Neutropenia Drug Value Chain Analysis
  2. 12.1.1 Chemotherapy Induced Neutropenia Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Chemotherapy Induced Neutropenia Drug Production Mode & Process
  7. 12.2 Chemotherapy Induced Neutropenia Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Chemotherapy Induced Neutropenia Drug Distributors
  10. 12.2.3 Chemotherapy Induced Neutropenia Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst